Europe's STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
Brief's Brad Smith and Brian Sozzi examine the top stories on Wall Street, providing investors with a quick overview of what they need to know. Xerox (XRX) is set to acquire Lexmark in a $1.5 billion ...
European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback